Mast Cell Disease Treatment: The Rise of Targeted Care
Mast cell disease treatment is entering a transformative new era as precision medicine reshapes how clinicians approach these rare and complex immune disorders. Mast cell disease encompasses a spectrum of disorders characterized by the abnormal accumulation, activation, or both of mast cells in tissues throughout the body.
The most common and clinically significant form is systemic mastocytosis (SM), a rare clonal mast cell disorder in which excess mast cells infiltrate the skin, bone marrow, liver, spleen, and other organs. Until recently, patients with systemic mastocytosis had very limited disease-modifying treatment options, relying primarily on antihistamines, mast cell stabilizers, and corticosteroids for treatment for mast cell flare ups without addressing the underlying disease process.
The last several years have brought a seismic shift in this landscape, with new treatments for mast cell disease and targeted therapy for mast cell disease now approved or on the horizon. These advances are giving patients and specialists new tools to manage symptoms, reduce mast cell burden, and improve quality of life through more personalized approaches.
Understanding the Biology: The KIT D816V Mutation
In more than 95% of patients with systemic mastocytosis, a single point mutation in the KIT gene, the D816V mutation, is the underlying driver of disease. KIT (also known as c-KIT or CD117) is a receptor tyrosine kinase expressed on mast cells; when activated, it promotes mast cell survival, proliferation, and function.
The D816V mutation causes constitutive (always-on) activation of KIT, leading to uncontrolled expansion of mast cells even in the absence of normal activating signals. This discovery provided a clear molecular targeted therapy for systemic mastocytosis: inhibit the mutant KIT D816V, and you can directly reduce the mast cell burden and the symptoms it causes.
Board-certified dermatologists’ understanding of these molecular mechanisms has also accelerated the development of mast cell activation syndrome treatment strategies and other forms of advanced treatment for rare immune disorders now emerging in specialty care settings.
Avapritinib: The First Approved Targeted Therapy for Systemic Mastocytosis
Avapritinib (brand name Ayvakit) is a highly selective oral tyrosine kinase inhibitor designed specifically to block the KIT D816V mutation. It was initially approved by the FDA in 2021 at a dose of 200 mg daily for advanced systemic mastocytosis – an umbrella term covering aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia. In 2023, a major milestone was reached: avapritinib became the first treatment ever approved specifically for indolent systemic mastocytosis (ISM) at a lower dose of 25 mg daily, giving patients with this more common and chronic form of the disease their first FDA-approved targeted therapy for mast cell disease.
Clinical trial data from the PIONEER trial demonstrated that avapritinib significantly reduces mast cell burden, lowers serum tryptase (a key biomarker of mast cell activity), and meaningfully improves patient-reported quality of life measures including, fatigue, pain, and symptoms of mast cell mediator release such as flushing, itching, and gastrointestinal disturbances.
Data from the longer-term PATHFINDER trial for advanced SM showed improved overall survival compared to prior mastocytosis treatment options. Importantly, avapritinib has also shown benefits for bone density, an important consideration given that systemic mastocytosis frequently causes osteopenia and osteoporosis due to mast cell infiltration of bone marrow.
Side effects of avapritinib can include cognitive effects such as brain fog, confusion, and dizziness in some patients, a consequence of the drug crossing the blood-brain barrier, which occurs in approximately 50% of patients to some degree. These neurological effects, while often mild, have been a driver of interest in developing next-generation agents with a more favorable tolerability profile.
Patients searching for a mast cell disease specialist near Chapel Hill, a mastocytosis treatment clinic in Chapel Hill, or an immunology specialist for mast cell disorders are increasingly seeking these newer therapies through multidisciplinary care teams that include allergy, immunology, hematology, and dermatology expertise.
Bezuclastinib: A Next-Generation KIT Inhibitor
Bezuclastinib (CGT9486), developed by Cogent Biosciences, represents one of the most promising new treatments for mast cell disease. Like avapritinib, it is a selective oral KIT D816V inhibitor and an emerging targeted therapy for systemic mastocytosis. However, bezuclastinib is designed not to cross the blood-brain barrier, which investigators believe may significantly reduce the neurological side effects associated with avapritinib.
Results from the Phase 2 SUMMIT trial have generated considerable excitement among clinicians and researchers focused on mast cell disease treatment. Top-line data released in July 2025 showed that patients with non-advanced systemic mastocytosis (including indolent SM, bone marrow mastocytosis, and smoldering SM) who received bezuclastinib achieved a statistically significant improvement in total symptom score (24.3 points vs 15.4 points in the placebo arm, p=0.0002).
Crucially, 76% of patients receiving bezuclastinib achieved at least a 50% reduction in symptoms – a rate described by investigators as unprecedented compared to prior therapies. The drug also demonstrated significant reductions in serum tryptase, bone marrow mast cell aggregates, and KIT D816V variant allele frequency.
Based on these compelling data, the FDA granted bezuclastinib Breakthrough Therapy Designation for non-advanced systemic mastocytosis, including patients who had previously received avapritinib and those with smoldering SM – two populations that currently have no approved standard of care. Cogent Biosciences announced plans to submit a New Drug Application to the FDA by the end of 2025, potentially paving the way for regulatory approval in 2026. These developments further reinforce the rapid evolution of targeted therapy for mast cell disease.
Elenestinib: Another Second-Generation Option in Development
Elenestinib (BLU-263), developed by Blueprint Medicines, the same company that created avapritinib, is another next-generation selective KIT D816V inhibitor under investigation as part of new treatments for mast cell disease. Like bezuclastinib, elenestinib is designed with limited blood-brain barrier penetration, potentially offering a safer neurological profile than its predecessor.
It is currently being evaluated in two major clinical trials: the HARBOR trial for indolent SM and the AZURE trial for advanced SM and other KIT-altered hematologic malignancies. Both trials are actively enrolling, and early data have shown promising efficacy with a favorable side effect profile.
As these studies progress, elenestinib may become another important targeted therapy for systemic mastocytosis, expanding the range of mastocytosis treatment options available to patients with both advanced and non-advanced disease.
Beyond KIT: Emerging Approaches
While KIT inhibitors dominate the current therapeutic pipeline for systemic mastocytosis, researchers are exploring additional targets. TL-895, a Bruton’s tyrosine kinase (BTK) inhibitor, is being studied in a Phase 2 trial for SM. BTK plays a role in mast cell activation and mediator release, distinct from the proliferative effects driven by KIT, and BTK inhibition may complement KIT-directed therapy or serve patients who do not respond to KIT inhibitors. Other investigational approaches include targeting interleukin-6 (IL-6), mTOR, and surface molecules specific to mast cells, such as sialic acid-binding immunoglobulin-like lectin-8 (siglec-8), targeted by the antibody lirentelimab.
For patients with mast cell activation syndrome (MCAS), a related but distinct disorder characterized by recurrent episodes of mast cell mediator release without the clonal expansion seen in systemic mastocytosis, treatment remains largely symptom-based. However, as our understanding of MCAS deepens and biomarkers improve, targeted therapies may eventually play a role here as well.
Managing Mast Cell Disease at Trillium Dermatology
Mast cell disease treatment is complex, heterogeneous, and often underdiagnosed. Symptoms can mimic many other conditions, including allergic disorders, irritable bowel syndrome, and fibromyalgia, leading to diagnostic delays that are frustrating for patients and their families.
A thorough diagnostic workup, including serum tryptase measurement, bone marrow biopsy when indicated, and KIT D816V mutation testing, is essential to accurate classification and to guide targeted therapy for mast cell disease and determine the most appropriate long-term management approach.
At Trillium Dermatology, a trusted dermatology clinic near Chapel Hill, our specialists in dermatology are experienced in evaluating patients with suspected or confirmed mast cell disorders, including systemic mastocytosis, cutaneous mastocytosis (including urticaria pigmentosa), and mast cell activation syndrome. We stay current on evolving diagnostic criteria, new treatments for mast cell disease, and emerging mastocytosis treatment options, including the rapidly expanding pipeline of precision therapies.
If you experience recurrent unexplained flushing, anaphylaxis, skin lesions that itch or blush with friction (Darier’s sign), chronic gastrointestinal symptoms, bone pain, or other features suggestive of mast cell involvement, please reach out to schedule a consultation.
FAQs
Mast cell disease refers to a group of disorders involving abnormal mast cell activation, accumulation, or both. Conditions may include systemic mastocytosis, cutaneous mastocytosis, and mast cell activation syndrome (MCAS).
Recent new treatments for mast cell disease include targeted KIT inhibitors such as avapritinib and investigational therapies like bezuclastinib and elenestinib. These therapies are designed to target the molecular drivers of disease more precisely than older symptom-based approaches.
Targeted therapy for systemic mastocytosis focuses on blocking specific mutations, most commonly KIT D816V, that drive abnormal mast cell growth and activation. These treatments may reduce mast cell burden, improve symptoms, and enhance quality of life.
Mast cell activation syndrome treatment often includes antihistamines, mast cell stabilizers, corticosteroids, and trigger avoidance. In some patients, additional therapies may be considered depending on symptom severity and associated conditions.
You should consider evaluation by a mast cell disease specialist near Chapel Hill or an allergy and immunology clinic mast cell disease expert if you experience recurrent flushing, unexplained allergic reactions, chronic itching, gastrointestinal symptoms, or suspected mast cell flare-ups.
